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Abstract
Marine sponges have been considered as a gold mine
during the past 50 years, with respect to the diversity
of their secondary metabolites. The biological effects
of new metabolites from sponges have been reported
in hundreds of scientific papers, and they are re-
viewed here. Sponges have the potential to provide
future drugs against important diseases, such as
cancer, a range of viral diseases, malaria, and
inflammations. Although the molecular mode of
action of most metabolites is still unclear, for a
substantial number of compounds the mechanisms
by which they interfere with the pathogenesis of a
wide range of diseases have been reported. This
knowledge is one of the key factors necessary to
transform bioactive compounds into medicines.
Sponges produce a plethora of chemical compounds
with widely varying carbon skeletons, which have
been found to interfere with pathogenesis at many
different points. The fact that a particular disease
can be fought at different points increases the chance
of developing selective drugs for specific targets.
Key words: sponge medicine — natural product —
cancer — inflammation — virus
Introduction
The relationship between sponges and medicines goes
back to Alexandrian physicians and was thoroughly
describes by the Roman historian Plinius. Physicians
used sponges that were saturated with iodine to
stimulate coagulation of the blood, or with bioactive
plant extracts to anesthetize patients. Sponges were
soaked with pure wine and put on the left part of the
chest in case of heartaches and soaked in urine to treat
bites of poisonous animals. Plinius recommended the
use of sponges against sunstrokes, and they were used
against all kinds of wounds, bone fractures, dropsy,
stomach aches, infectious diseases, and testicular
tumors (Hofrichter and Sidri, 2001), or even as im-
plants after breast operations (Arndt, 1938). At least
since the 18th century, Russian, Ukrainian, and Pol-
ish physicians have used a freshwater sponge they call
Badiaga (Figure 1) for the treatment of patients (Noz-
eman, 1788). The dry powder of this sponge is rubbed
on the chest or back of patients with lung diseases or
on the sore places in cases of foot and leg aches (such as
rheumatism (Schroder, 1942). Oficjalski (1937) dis-
covered that Badiaga is not really one sponge, but
mixtures of several freshwater sponges that differ
depending on the region. In Poland it consisted of
powder of Euspongilla lacustris, Ephydatia fluviatil-
is, and Meyenia muelleri, while the Russian Badiaga
was a mixture of Euspongilla lacustris, Ephydatia
fluviatilis, Spongilla fragilis, and Carterius stepan-
owi. He suggested that the high iodine concentration
in all sponge species gives rise to the wholesome effect
of Badiaga. At present Stodal, syrup containing roasted
Spongia officinalis, is used for homeopathic treat-
ment of dry and asthmatic cough in the Western world
(Stodal, 2003).
Pharmaceutical interest in sponges was aroused
in the early 1950s by the discovery of a nucleosides
spongothymidine and spongouridine in the marine
sponge Cryptotethia crypta (Bergmann and Feeney,
1950, 1951). These nucleosides were the basis for
the synthesis of Ara-C, the first marine-derived
anticancer agent, and the antiviral drug Ara-A
(Proksch et al., 2002). Ara-C is currently used in the
routine treatment of patients with leukemia and
lymphoma. One of its fluorinated derivatives has
also been approved for use in patients with pan-
Correspondence to: Detmer Sipkema; E-mail: detmer.sipkema@
wur.nl
142 DOI: 10.1007/s10126-004-0405-5  Volume 7, 142–162 (2005)  Springer Science+Business Media, Inc. 2005
creatic, breast, bladder, and lung cancer (Schwarts-
mann, 2000). At the same time it was revealed that
certain lipid components such as fatty acids, sterols
and other unsaponifiable compounds occur in lower
invertebrates in a diversity far greater than that
encountered among animals of higher organization
(Bergmann and Swift, 1951). These early promises
have now been substantiated by an overwhelming
number of bioactive compounds that have been
discovered in marine organisms. More than 15,000
marine products have been described thus for
(MarinLit, 1999; Faulkner, 2000, 2001, 2002).
Sponges, in particular, are responsible for more than
5300 different products, and every year hundreds of
new compounds are being discovered (Faulkner
2000, 2001, 2002).
Most bioactive compounds from sponges can be
classified as antiinflammatory, antitumor, immu-
nosuppressive or neurosuppressive, antiviral, anti-
malarial, antibiotic, or antifouling. The chemical
diversity of sponge products is remarkable. In addi-
tion to the unusual nucleosides, bioactive terpenes,
sterols, cyclic peptides, alkaloids, fatty acids, perox-
ides, and amino acid derivatives (which are fre-
quently halogenated) have been described from
sponges (Figure 2).
For this review we have surveyed the discov-
eries of products derived from marine sponges up
to now, and attempted to show the variety of po-
tential medical applications of metabolites from
sponges and the mechanisms by which they
interfere with the pathogenesis of human diseases.
This knowledge is a prerequisite for the develop-
ment of a drug from a bioactive compound. For
example, many secondary metabolites inhibit
growth of cancer cell lines, but this does not imply
Fig. 1. Examples of homeopathic drugs based on sponge
extracts currently in use (Badiaga and Stodal syrup).
Fig. 2. An illustration of the chemical diversity of sponge-derived molecules. a: Xestospongin C (Xestospongia sp. /
macrocyclic bis-oxaquinolizidine. b: Spongothymidine (Cryptotethia crypta / unusual nucleoside). c: discorhabdin D
(Latrunculia brevis; Prianos sp. / fused pyrrolophenanthroline alkaloid. d: Contignasterol (Petrosia contignata / oxy-
genated sterol). e: Jaspamide (Hemiastrella minor / macrocyclic lactam/lactone). f: agelasphin (Agelas mauritianus / a-
galactosylceramide).
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that they will be suitable as a medicine against
cancer, because they may exhibit important side
effects. The following sections summarize com-
pounds by disease type and describe their mode of
action, and discuss the reasons why sponges would
produce these metabolites.
Sponge Products
Antiinflammatory Compounds. Acute inflamma-
tions in the human body can result from microbial
infection, physical damage, or chemical agents. The
body reacts by changing the blood flow, increasing
the permeability of blood vessels, and allowing the
escape of cells from the blood into the tissues (Tan et
al., 1999). Chronic inflammation of the skin or joints
may severely damage the body if it leads to psoriasis
or rheumatic arthritis (Pope et at., 1999). Sponges
have proved to be an interesting source of antiin-
flammatory compounds (Table 1).
Manoalide, one of the first sesterterpenoids to be
isolated from a marine sponge (Luffariella variabi-
lis), was found to be an antibiotic (De Silva and
Scheuer, 1980) and an analgesic (Mayer and Jacobs,
1988). In addition, its antiinflammatory properties
have been studied extensively (Bennet et al., 1987).
The antiinflammatory action is based on the irre-
versible inhibition of the release of arachidonic acid
from membrane phospholipids by preventing the
enzyme phospholipase A2 from binding to the
membranes (Glaser et al., 1989). A rise in the intra-
cellular arachidonic acid concentration would lead
to upregulation of the synthesis of inflammation
mediators as prostaglandins and leukotrienes (Fig-
ure 3). Phospholipase A2 inhibition has been re-
corded for many sesterterpenes from sponges of the
order Dictyoceratida, but also for bis-indole alkaloids
such as topsentin (Jacobs et al., 1994). The mecha-
nism by which they affect the inflammation process
is different from commonly used nonsteroidal anti-
inflammatory drugs. Only a few sponge-derived
terpenoids have been found to inhibit lipoxygenase,
another enzyme that is involved in the inflamma-
tory response (Carroll et al., 2001).
The antiinflammatory sponge products are selec-
tive inhibitors of specific enzymes of a range of dis-
eases, like psoriasis or rheumatic arthritis. The
currently used nonsteroidal antiinflammatory drugs
often fail to control the disease and present important
side effects such as risk of gastrointestinal bleeding
and renal complications (De Rosa, 2002). These are
caused by unselective inhibition of cyclooxygenases,
some of which are also involved in the promotion of
the production of the natural mucus that protects the
gastrointestinal tract (Bjarnason et al., 1993). Ta
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Antitumor Compounds. A number of isolated
sponge compounds are inhibitors of protein kinase
C (PKC). PKC inhibitors have attracted interest
worldwide, as there is evidence that too high levels
of PKC enzyme are involved both in the patho-
genesis of arthritis and psoriasis (owing to regula-
tion of phospholipase A2 activity), and in tumor
development (Bradshaw et al., 1993; Yoshiji et al.,
1999). PKC is believed to be the receptor protein of
tumor-promoting phorbol esters, and PKC inhibi-
tors prevent binding of carcinosarcoma cells to the
endothelium (B. Liu et al., 1991). Glycosylation of
the receptors, and especially the presence of fucose
residues, plays an important role in the binding of
carcinosarcoma cells and leukocytes to the
receptors in the endothelium (Springer and Lasky,
1991).
Fucosyltransferase inhibitors, such as the octa-
and nonaprenylhydroquinone sulfates that were
isolated from a Sarcotragus sp. (Wakimoto et al.,
1999), may therefore be promising candidates for
controlling inflammatory processes such as arthritis
or for combating tumor growth.
In addition to PKC inhibitors and fucosyl trans-
ferase inhibitors, numerous anticancer molecules
with a different mode of action have been discovered
in marine sponges (Table 2). These compounds can
be divided in 3 classes:
(1) nonspecific inhibitors of cell growth; (2) spe-
cific inhibitors of cancer cells; and (3) inhibitors of
cancer cells of a certain type of cancer (as the
aforementioned PKC inhibitors).
Many nonspecific cell growth inhibitors have
been discovered in sponges. They are valuable for
treating cancer under certain conditions, but they
also affect the division of healthy cells. Therefore,
their applications are limited, depending on their
specific characteristics. The cytoskeleton is an
interesting target for cancer therapy, as the micro-
tubules and microfilaments are involved in cellular
organization during cell division. A number of ado-
ciasulfates (triterpenoid hydroquinones) from a
Haticlona sp. were the first inhibitors of the kinesin
motor protein to be discovered. These toxins are
believed to inhibit the protein by binding to the
microtubule binding site, ‘‘locking up’’ the proteins
motor function, and thereby blocking cell division
(Blackburn et al., 1999). In addition to these triterp-
enoid hydroquinones, a number of potent microtu-
bule-interfering compounds have been discovered in
marine sponges, such as halichondrin B (Bai et al.,
1991), spongistatin (Bai et al., 1993), discodermolide
(Ter Haar et al., 1996), laulimalide (Moobeny et al.,
1999), peloruside A (Hood et al., 2002), and dict-
yostatin (Isbrucker et al., 2003). Other metabolites,
such as latrunculin A from Latrunculia magnifica
(Coue et al., 1987) and swinholide A from Theonella
swinhoei (Bubb et al., 1998), disrupt the polymeri-
zation of actin. Actin which is the key element of
the microfilaments, and it can block many cellular
processes including cell division. Spongiacidin B
(Inaba et al., 1998) and fascaplysin (Soni et al., 2000)
are examples of sponge-derived metabolites that in-
hibit cell division by inhibition of cyclin-dependent
kinase 4, which leads to arrest of cells in the G1
phase. Other metabolites, such as mycalamide
(Burres and Clement, 1989) and aragusterol (Fukuoka
et al., 2000), disturb cell division by inhibition of
protein synthesis. Neoamphimedine (De Guzman et
al., 1999) and elenic acid (Juagdan et al., 1995) inhibit
the development of tumors by blocking topoisom-
erase II, the nuclear enzyme which makes transient
DNA breaks that are required for replication (L.F.
Liu and Chen, 1994).
Nitric oxide synthetase inhibitors, such as the
imidazole alkaloid Na amine D that was isolated from
the calcareous sponge Leucetta cf. chagosensis
(Dunbar et al., 2000), are not involved in growth
inhibition of cancer cells, but may prevent events in
the early phases of tumorigenesis. Nitric oxide could
participate in the tumorigenesis by mediating DNA
Fig. 3. Inflammatory cascade inside the cell. Phospholipase
A2 (PLA2) catalyzes the release of membrane-bound arachi-
donic acid (AA) to free arachidonic acid. Arachidonic acid is
converted to leukotrienes andprostaglandins bylipoxygenase
(LOX) and cyclooxygenase-2 (COX-2), respectively. Sponge-
derived antiinflammatory molecules are mainly inhibitors of
PLA2 or LOX, while nonsteroidal antiinflammatory drugs
inhibit COX-2, but also the constitutive COX-1.
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damage and support tumor progression through the
induction of angiogenesis (Lala and Orucevic, 1998).
However, inhibition of nitric oxide synthetase may
also affect other physiologic processes in which nitric
oxide is involved, such as intracellular or transcellular
messaging, and it is involved in regulation of the
immunogenic respons by T lymphocytes. Agelasphin
(KRN7000) from Agelas mauritianus (E. Kobayashi et
al., 1995) has been found to stimulate the immune
system by activation of dendritic and natural killer T
(NKT) cells. The NKT cell level is lower in the blood of
patients with cancer or autoimmune disease, such as
type 1 diabetes (Shimosaka, 2002), and in mice it was
shown that tumors could be rejected by stimulation of
the immune system by agelasphin (Yamaguchi et al.,
1996).
The activity of other compounds is more spe-
cific toward tumor cells. Multidrug resistance in
human carcinoma cells caused by overexpression of
two kinds of membrane glycoproteins is reversed by
agosterol A from the marine sponge Spongia sp. It
has been suggested that an altered cytosolic pH
plays a role in drug resistance. Vascular (H+) AT-
Pase (v-ATPase) is an enzyme involved in many
cellular processes that are often upregulated in
cancer cells, such as acidic vesicular organelle for-
mation, which is a response to radiation injury or
manipulation of the pH to decrease entry of che-
motherapeutics into the cells (Martinez-Zaguilan et
al., 1999). Salicylihamide A was isolated from a
Haliclona sp. as a selective inhibitor of v-ATPase
and has been shown to be 60-fold more cytotoxic to
certain cancer cells than to their normal noncan-
cerous counterparts (Erickson et al., 1997). The first
natural 6-hydroximino-4-en-3-one steroids were
isolated from Cinachyrella spp. (Rodriguez et al.,
1997) and are examples of molecules that can be
deployed against a specific type of cancer. They
displayed high affinity to aromatase (Holland et al.,
1992), which is the rate-limiting enzyme that cat-
alyzes the conversion of androgens to estrogens
(Figure 4). Blockade of this step allows treatment of
hormone-sensitive breast cancer that is dependent
on estrogen (Lonning et al., 2003). A peculiar fact
about the 6-hydroximi no-4-en-3-one steroids is
that they were chemically synthesized before they
were even discovered in nature.
In addition, many more compounds that dis-
played growth inhibition activity of tumor cell lines
have been isolated (Table 2), although their exact
effects are still unclear. Discorhabdin D (Perry et al.,
1988), chondropsin A and B (Cantrell et al., 2000),
haligramides A and B (Rashid et al., 2000), and gla-
ciasterols A and B (Pika et al., 1992) are only a few
examples of these molecules.Ta
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Immunosuppressive Compounds. In addition to
their potential for treatment of cancer, nitric oxide
synthetase inhibitors downregulate T-cells are, sup-
pressing the immune system, and they diminish the
fierceness of migraine attacks (Griffith and Gross,
1996). Immune system suppression is desired in
cases of hypersensitivity to certain antigens (e.g.,
allergies) or organ transplantations. Patients who
receive a donor organ need life-long medication to
prevent rejection by the immune system, and for
that reason it is extremely important that these
medicines are very specific suppressors. Therefore
there is a continuous demand for new immunosup-
pressives. A number of new molecules with immu-
nosuppressive activity, which interfere at different
points of the immune response have been discovered
in marine sponges (Table 3; Figure 5).
Three polyoxygenated sterols from a Dysidea sp.
from Northern Australia are selective immunosup-
pressive compounds that inhibit the binding of
interleukin 8 (IL-8), a cytokine that attracts neu-
trophils into an area of tissue injury, to the IL-8
receptor (Leone et al., 2000). The simplexides from
the Caribbean sponge Plakortis simplex are a group
of immunosuppressive glycolipids that inhibit pro-
liferation of activated T cells by a noncytotoxic
mechanism (Costantino et al., 1999). Pateamine A,
from a Mycale sp., inhibits the production of IL-2
(Romo et al., 1998) and thereby the activation of
resting T cells and B cells to a lesser extent. Conti-
gnasterol from Petrosia contignata (Burgoyne and
Andersen, 1992) inhibits allergen-induced histamine
release from rat mast cells (Takei et al., 1994) and
from guinea-pig lung tissue in vitro (Bramley et al.,
1995), and the activation of eosinophils into airways
in guinea-pigs and could be used to treat asthma
(Langlands et al., 1995).
Cardiovascular Agents. In addition to regula-
tors of the white blood cells, a number of sponge-
derived molecules have been found to interfere with
other blood-related diseases such as thrombosis,
atherosclerosis, or diabetes (Table 4). The process of
blood coagulation is triggered by a complex proteo-
lytic cascade that leads to the formation of fibrin.
Thrombin is a serine protease that cleaves a peptide
fragment from fibrinogen, which then leads to the
generation of fibrin, a major component of blood
clots (Shuman et al., 1993). Cyclotheonarnide A,
Fig. 4. Inhibition of breast cancer by Cinachyrella sp. ste-
roids. Aromatase is the key enzyme in the formation of the
estrogens estrone (E1) and estradiol (E2). It catalyzes the
final steps, from androstenedione (A) to estron and from
testosterone (T) to estradiol, in the estrogen pathway.
Estrogen conversion can occur in the blood, in normal
breast tissue, as well as in breast tumor tissue (adapted
from Geisler, 2003). The 6-hydroximino-4-en-3-one ste-
roids from Cinachyrella sp. are inhibitors of aromatase.
The inhibition of aromatase in the tumor tissue is not
shown to maintain the clarity of the illustration.
Table 3. Examples of Immunosuppressive Products from Sponges
Compound Compound class Species/order Mode of action Reference
Simplexides Glycolipid Plakortis simplex/
Homosclerophorida
Inhibitor of T-cell
proliferation
Costantino et al.,
1999
Polyoxygenated
sterols
Sterol Dysidea sp./
Dendroceratida
IL-8 inhibitor Leone et al., 2000
Contignasterol Oxygenated
sterol
Petrosia contignata/
Haplosclerida
Histamine release
inhibitor
Takei et al., 1994;
Bramley et al., 1995
Xestobergsterols
A and B
Pentacyclic
sterol
Xestosponga berquistia/
Haplosclerida
Histamine release
inhibitor
Shoji et al., 1992
Taurodispacamide A Pyrrole-imidazole
alkaloid
Agelas oroides/Agelasida IL-2 inhibitor Fattorusso and
Taglialatela-Scafati,
2000
Pateamine A Thiazole macrolide Mycale sp./Poecilosclerida IL-2 inhibitor Northcote et al., 1991
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isolated from a Theonella sp. (Fusetani et al., 1990),
represents an unusual class of serine protease
inhibitors and is a potential drug for the treatment of
thrombosis (Maryanoff et al., 1993). Eryloside F from
Erylus formosus was found to be a potent thrombin
receptor antagonist (Stead et al., 2000). Thrombin
receptor activation is likely to play a key role not
only in arterial thrombosis but also in atherosclero-
sis (Chackalamannil, 2001). Atherosclerosis starts
with damage to the endothelium and subsequent
deposition of fats, cholesterol platelets, cellular
waste products, calcium, and other substances in the
artery wall. These may stimulate endothelial cells to
produce a vascular cell adhesion molecule that re-
sults in further buildup of cells and shrinkage of the
arterial diameter (Zapolska-Downar et al., 2001).
Halichlorine from Halichondria okadai is an inhib-
itor of the expression of vascular cell adhesion
molecule 1 (Kuramoto et al., 1996) and may thus
impede atherogenesis (Arimoto et al., 1998).
Callyspongynic acid, isolated from Callyspongia
truncata, is an a-glucosidase inhibitor (Nakao et al.,
2002). a-Glucosidase inhibitors interfere with the
hydrolysis of glycogen, keeping the glucose concen-
tration in the blood at a lower level, and can be used
to treat patients with diabetes (Lebovitz, 1992).
Neurosuppressive Compounds. Keramidine,
isolated from an Agelas sp. (Nakamura et al.,
1984), is an example of a number of neurosup-
pressive compounds that have been isolated from
marine sponges (Table 5). It is a serotonergic
receptor antagonist and blocks serotonin-mediated
neural communication. Several different serotonin
receptors have been identified. They are related to
(1) platelet aggregation, and may therefore be use-
ful against thrombosis (Ruomei et al., 1996); (2)
smooth muscle contraction (Garcia-Colunga and
Miledi, 1996); (3) vomiting, owing to their presence
in the gastrointestinal tract (Lang and Marvig,
Fig. 5. Simplified representation of the immune respons after capture of an antigen by macrophages (M). Both macro-
phages, but especially T-helper cells (T-help), secrete many interleukins (IL-x) or macrophage activation factor (MAP), to
trigger the primary immune response via neutrophils (N), or the secondary immune respons by activating resting T cells
(T-rest) and B cells (B). Activated B cells secrete antibodies that bind to macrophages that have phagocytized an antigen,
and they are subsequently destroyed by T-killer cells (T-kill). Mast cells (Mast) release histamine as a response to binding
of an antigen to IgE molecules present in their cell membranes. The black crosses indicate position where sponge-derived
immunosuppressive compounds interfere with the immune response.
Table 4. Examples of Sponge Products that Affect Blood-Related Diseases
Compound Compound class Species/order Mode of Action Reference
Cyclotheonamide A Cyclic pentapeptide Theonella sp./
Lithistida
Serine protease
inhibitor
Maryanoff et al., 1993
Eryloside F Penasterol
disaccharide
Eryltus formosus/
Astrophorida
Thrombin receptor
antagonist
Stead et al., 2000
Halichlorine Cyclic aza-polyketide Halichondria okadai/
Halichondrida
VCAM-1 inhibitor Arimoto et al., 1998
Callyspongynic
acid
Polyacetylene Callyspongia truncata/
Haplosclerida
a-glucosidase inhibitora Nakao et al., 2002
aAlso has potential antiviral activity.
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1989); (4) and most interestingly, may function as
antidepressant drugs in the brain (Nagayama et al.,
1980).
Dysiherbaine from Dysidea herbacea (Sakai et
al., 1997) is a potent excitatory amino acid that
causes seizures by interfering with the L-glutamate-
based neurotransmitter communication and may
provide a lead compound in therapeutical agents for
neurologic disorders (Sakai et al., 2001).
Muscle Relaxants. Disturbances in neuromus-
cular communication resulting from stress cause
permanent muscle activation (Lundberg, 1995; Edgar
et al., 2002). In addition to the above-mentioned
centrally acting muscle relaxants, which mediate
neuromuscular communication, peripherally acting
muscle relaxant may be used for local muscle
relaxation. They are applied for relief of strokes, or
during intubations and surgery (Frakes, 2001). 1-
Methylguanosine from Tedania digitata (Quinn et
al., 1980) and xestospongin C, which was isolated
from a Xestospongia sp. (Gafni et al., 1997), are
examples of muscle relaxants that discovered in
sponges (Table 5). Xestospongin C is a potent
inhibitor of the inositol 1,4,5-triphosphate (IP3)
receptors and the endoplasmic-reticulum Ca2+
pumps (De Smet et al., 1999) and inhibits IP3-in-
duced increase in the oscillatory contraction of
muscles (Miyamoto et al., 2000). ß-Adrenoreceptor
agonists, such as S1319 isolated from a Dysidea sp.
(Suzuki et al., 1999), have utero-relaxant properties,
which can be therapeutically used for the preterm
delivery of infants (Dennedy et al., 2002), and are
widely used as antiasthmatic drugs (Suzuki et al.,
1999). However, owing to their low selectivity ß-
adrenoreceptor agonists may have severe side effects
such as arterial hypertension, corony heart disease,
and tachycardia (Borchard, 1998). Therefore, there is
continued interest in finding more selective ß-adre-
noreceptor agonists such as S1319.
Antiviral Compounds. Sponges are also a rich
source of compounds with antiviral properties (Ta-
ble 6). The high number of HIV-inhibiting com-
pounds discovered does not reflect greater potential
of sponges to fight AIDS compared with other viral
diseases, but rather the interest of many researchers.
The strong focus on screening for anti-HIV activity
has led to discovery of numerous compounds, but the
mechanism of inhibition is still poorly characterized.
Papuamides C and D (Ford et al., 1999), haplosamates
A and B (Qureshi and Faulkner, 1999), and avarol
(Muller et al., 1987), which has also been patented as
antipsoriasis (Muller et al., 1991), are examples of
HIV-inhibiting compounds from different sponges.
Avarol is one of the few compounds for which the
mechanism by which it inhibits progression of HIV
infection is more or less known. In vitro and animal
data indicate that avarol combines useful properties
of an increased humoral immune response, as IgG
and IgM production is significantly increased, and
interference with the posttranscriptional processes of
viral infection (Muller et al., 1987). Avarol inhibits
HIV by almost completely blocking the synthesis of
the natural UAG suppressor glutamine transfer
tRNA. Synthesis of this tRNA is upregulated after
viral infection, and it is important for the synthesis of
a viral protease, which is necessary for viral prolif-
eration (Muller and Schroder, 1991). Low concentra-
tions of only 0.9 and 0.3 lM avarol resulted in 80%
and 50% inhibition of virus release from infected
cells, respectively (Schroder et al., 1991), while
Table 5. Examples of Neurosuppressives and Muscle Relaxants from Sponges
Compound Compound class Species/order Mode of action Reference
Dysiherbaine Unusual amino acid Dysidea herbacea/
Dendroceratida
Glutamate receptor
antagonist
Sakai et al., 1997
Keramadine Pyrrole-guanidine
alkaloid
Agelas sp. / Agelasida Serotonergic receptor
antagonist
Nakamura et al.,
1984
1-Methylisoguanosine Nucleoside analogue Tedania digitata /
Poecilosclerida
Unknown (muscle
relaxant, antiallergic)
Quinn et al., 1980
Xestospongin C Macrocyclic
bis-oxaquinolizidine
Xestospongia sp./
Haplosclerida
IP3-inhibitor De Smet et al.,1999
Okinonellin B Furanosesterterpenoid Spongionella sp./
Dendroceratida
Unknown (muscle
relaxant)
Kato et al., 1986
Bromotopsentin Bis-indole alkaloid Spongosorites sp./
Halichondrida
a1-Adrenergic receptor
antagonist
Phife et al., 1996
Penaresidin A Azetidine alkaloid Penares sp./
Astrophorida
Actomyosin ATPase
inhibitor
Kobayashi et al., 1991
S1319 Benzothiazole
derivative
Dysidea sp./
Dendroceratida
Unknown
(antiasthmatic,
uterine relaxation)
Suzuki et al., 1999
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uninfected cells were highly resistant against avarol
(Muller et al., 1985; Kuchino et al., 1988). Further-
more, it was shown that the avarol derivatives, 6¢-
hydroxy avarol and 3¢-hydroxy avarone (Figure 6),
were very potent inhibitors of HIV reverse trans-
criptase. This enzyme has a key role in the early
stages of HIV infection and is a specific target for
antiviral drugs, as it is responsible for converting the
viral genomic RNA into proviral double-stranded
DNA, which is subsequently integrated into the host
chromosomal DNA (Loya and Hizi, 1990).
In addition to their applications to treat diabetes,
a-glucosidase inhibitors, such as callyspongymc
acid, are potentially broad-based antiviral agents.
They disturb protein glycosylation and cause some
viral envelope proteins to be misfolded, which leads
to arrest of these proteins within the endoplasmic
reticulum, where protein folding takes place. It has
been demonstrated that alteration of the glycosyla-
tion pattern of HIV, hepatitis B virus, and bovine
viral diarrhea virus by a-glucosidase inhibitors
attenuates viral infectivity (Ratner et al., 1991; Me-
hta et al., 1998).
A very different class of virus inhibitors that has
been found in many different sponges are 2¢-5¢ oli-
goadenylates (2–5A), which are involved in the
interferon-mediated response against a wide range of
viruses in mammals. The antiviral action is based on
the activation of a latent endoribonuclease that
prevents viral replication by degradation of its
mRNA as well as cellular RNA (Kelve et al., 2003).
For many other antivirals, the mechanism of inhi-
bition is still unclear, but they are active against
range of viruses. Hamigeran B from Hamigera ta-
rangaensis, for example, showed 100 % in vitro
inhibition against both the herpes and polio viruses
(Wellington et al., 2000), and the weinbersterols A
and B from Petrosia weinbergi exhibited in vitro
activity against feline leukemia virus, mouse influ-
enza virus, and mouse corona virus (Sun et al., 1991;
Koehn et al., 1991).
In general, antiviral molecules from sponges do
not give protection against viruses, but they may
result in drugs to treat already infected persons. In
addition, broad-based antiviral agents such as 2-5A
Fig. 6. Molecular structures of avarol (a: R1 = H) and 6¢-
hydroxy avarol (a: R1 = OH) and avarone (b: R1 = H) and 3¢-
hydroxy avarone (b: R1 = OH).
Table 6. Examples of Antiviral Products from Sponges
Compound Compound class Species/order Activity Reference
Dragmacidin F Indole alkaloid Halicortex sp./? Antiviral Cutignano et al.,
2000
Papuamides
C and D
Cyclic peptide Theonella mirabilis,
T. swinhoei/Lithistida
Antiviral (HIV-1) Ford et al., 1999
Mololipids Tyramine lipid ?/Verongida Antiviral (HIV-1) Ross et al., 2000
Haplosamates
A and B
Sulfamated steroid Xestospongia sp./
Haplosclerida
Antiviral (HIV-1
integrase inhibitor)
Qureshi and
Faulkner, 1999
Hamigeran B Phenolic macrolide Hamigera tarangaensis/
Poecilosclerida
Antiviral (herpes and
polio)
Wellington
et al., 2000
Weinbersterols
A and B
Sulfated sterol Petrosia weinbergi/
Haplosclerida
Antiviral (feline
leukemia, mouse
influenza, mouse
corona)
Sun et al., 1991
Variolin B Pyridopyrrolopyrimidine
alkaloid
Kirkpatrickia varialosa/
Poecilosclerida
Antiviral Perry et al., 1994
Avarol Hydroquinone,
sesquiterpenoid
Dysidea avara/
Dendroceratida
UAG suppressor
glutamine tRNA
inhibitora
Muller et al.,
1987 Muller
et al., 1991
2-5A 2¢, 5¢ Linked
oligonucleotide
Many sponges Interferon mediator Kelve et al., 2003
Hennoxazole A Bisoxazole Polyfibrospongia sp./
Dictyoceratida
Antiviral Ichiba et al., 1991
aAlso has antiinflammatory potential antitumor activity.
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and a-glucosidase inhibitors may be useful in cases
of sudden outbreaks of (unfamiliar) viruses like
SARS and Ebola.
Antimalarial Compounds. Several sponge-de-
rived antimalarial compounds have been discovered
during the last decade (Table 7). New antimalarial
drugs are needed to cope with the increasing number
of multidrug-resistant Plasmodium strains that
cause malaria. Plasmodium falciparum has become
resistant against chloroquinone, pyrimethamine,
and sulfadoxine (Bwijo et al., 2003). Kalihinol A from
a Acanthella sp. (Miyaoka et al., 1998) and a number
of terpenoid isocyanates, isothiocyanates, and iso-
nitriles from Cymbastela hooperi (Konig et al., 1996)
display selective in vitro antimalarial activity
against P. falciparum. Also a number of free car-
boxylic acids from Diacarnus levii were used as
precursors to yield new cyclic norditerpene perox-
ides after esterification. These epidioxy-substituted
norditerpenes and norsesterterpenes displayed
selective activity against both chloroquine-sensitive
and chloroquine-resistant P. falciparum strains (D
Ambrosio et al., 1998). The manzamines, the most
promising antimalarial compound, have been dis-
covered in a number of sponges (Sakai et al., 1986;
Ang et al., 2000; Youssaf et al., 2002). It has been
suggested that the antimalarial effect of manzamine
A is due to an enhanced immune response (Ang et
al., 2001).
Antibiotics and Fungicides. With respect to
antibiotics and fungicides, similar multiresistance
problems have concerned physicians for a long time.
Many new molecules with antibiotic properties are
discovered every year, but in marine sponges their
ubiquity is remarkable (Table 8). An early screening
by Burkholder and Ruetzler (1969) revealed that 18 of
31 sponges tested showed antimicrobial effects, of
which some were very strong against a range of
gram-positive and gram-negative bacteria. The added
value of some new sponge-derived antibiotics was
shown by the inhibitory effect of arenosclerins A–C
from Arenosclera brasiliensis on 12 antibiotic-
resistant bacteria isolated from a hospital (Torres et
al., 2002). Fungicides that are currently used are less
diverse than antimicrobials, and the use of many of
them is restricted because of toxic effects to humans,
animals, and plants (Nakagawa and Moore, 1995;
Rahden-Staron, 2002). It remains to be demonstrated
whether antifungals like topsentiasterols D and E
from Topsentia sp. (Fusetani et al., 1994), acanthos-
terol sulfates I and J from an Acanthodendrilla sp.
(Tsukamoto et al., 1998) or the macrolide leucasc-
androlide A from the calcareous sponge Leucascan-
dra caveolata (DAmbrosio et al., 1996) will have
different characteristics than the fungicides that are
currently used, but the fact that they are produced by
eukaryotic organism (if not produced by a symbiont)
may imply that they are less toxic to other nonfungal
eukaryotes.
Antifouling Compounds. A last class of bioac-
tive compounds from marine sponges are antifouling
molecules (Table 9). They are not associated with
the development of new drugs, but could be envi-
ronmentally friendly substitutes for chemical an-
tifoulants. Biofouling organisms such as blue
mussels, barnacles, and macroalgae cause serious
problems to ships hulls, cooling systems of power
plants, and aquaculture materials (Holmes, 1970;
Houghton, 1978). Long-term use of chemical an-
tifoulants has led to increased concentrations of
tributyltin and its current replacements in coastal
sediments (Konstantinou and Albanis, 2004) and to
mortality and change of sex of nontarget organisms
(Katranitsas et al., 2003). Natural marine antifouling
molecules have recently been reviewed (Fusetani,
2004) and may provide less toxic and more specific
antifouling activity. Sponge-derived antifouling
molecules have been found to inhibit the settlement
of barnacle larvae (Okino et al., 1995; Tsukamoto et
Table 7. Examples of Antimalarial Products from Sponges
Compound Compound class Species/order Reference
Axisonitrile-3 Sesquiterpenoid isocyanide Acanthella klethra/
Halichondrida
Angerhofer et al.,
1992
Manzamine A Manzamine alkaloid,
diterpene isocyanates,
isothiocyanates and
isonitriles, norditerpenoid
and norsesterterpenoid
endoperoxides
e.g., Haliclona sp./
Haplosclerida
Cymbastela hooperi/
Halichondrida
Diacarnus levii/
Poecilosclerida
Ang et al., 2001
Konig et al., 1996
D’Ambrosio
et al., 1998
Kalihinol A Isonitril-containing
kalihinane diterpenoid
Acanthella sp./
Halichondrida
Miyaoka et al., 1998
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al., 1996a, 1996b), inhibit fouling by macroalgae
(Hattori et al., 1998; Kubanek et al., 2002), or repell
the blue mussel Mytilus edulis galloprovincialis
(Sera et al., 1999).
Ecologic Role of Sponge Metabolites. Such an
extensive collection of sponge-derived bioactive
compounds raises the question of why sponges pro-
duce so many metabolites that can be useful to treat
our human diseases. The huge number of different
secondary metabolites discovered in marine sponges
and the complexity of the compounds and their
biosynthetic pathways (and corresponding kilobases
of DNA for the programming of their synthesis) can
be regarded as an indication of their importance for
survival. An obvious example of the benefits of their
secondary metabolites for the sponge itself, is the
presence of antifouling products. To safeguard their
water-pumping capacity, sponges cannot tolerate
biofilm formation or settlement of barnacles or bry-
ozoans on their surface (Proksch, 1994), The level of
cytotoxicity of some sponge products is high enough
to even create a bare zone around the sponge
(Thompson, 1985) that is maintained by the emis-
sion of a mucus containing the toxins (Sullivan et
al., 1981). This allows the conquest of densely pop-
ulated rocks or corals and competition with faster
growing organisms, but it is striking that the sponge
can selectively use its poisons without self-destruc-
tion.
Secondary metabolites can protect the organism
against predation, which is especially important for
physically unprotected sessile organisms like spon-
ges (Becerro et al., 1997). Relatively few animals,
such as the hawksbill turtle and some highly
evolved teleost fishes (Meylan, 1990), are largely
dependent on sponges for their diet. Also some nu-
dibranches feed on sponges and even manage to use
the sponges metabolites for their own chemical de-
fence (Pawlik et al., 1988). However, these spongi-
vores represent only a tiny fraction of the animals
inhabiting the seas. Secondary metabolites can also
protect their producers against bacteria, fungi, or
parasites (Davies, 1992). In sponges the role of the
chemical constituents is clouded by the complexity
of the sponge-symbiont relationship (Dumdei et al.,
1998). Many different bacterial species permanently
inhabit sponges and contribute considerably to the
total sponge biomass (Wilkinson, 1978). It has been
suggested that the growth of ‘‘useful’’ microorgan-
isms may be under control of the sponge host and
serve as source of food or supply other metabolic
products (Muller et al., 1981). However, it has also
been found that associated bacteria might be the
actual producers of a number of compounds thatT
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have been isolated from sponges. Oscillatoria
spongelia, a cyanobacterial symbiont that can con-
stitute up to 40% of Dysidea herbacea, is the pro-
ducer of antimicrobial polybrominated biphenyl
ethers and might keep the sponge free of other bac-
teria (Unson, et al., 1994).
For many products it is not yet known whether
they are produced by the sponge or by a symbiont. It
is clear, however, that sponges are responsible for the
production of a rich arsenal of ‘‘chemical weapons.’’
Their early appearance in evolution has given them a
lot of time for the development of an advanced
chemical defense system. It is interesting to note
that the synthesis of secondary metabolites is regu-
lated depending on conditions that the sponge
experiences. Specimens of Crambe crambe in well-
illuminated regions grow faster than their counter-
parts exposed to darker conditions, but the speci-
mens in the dark are better defended as they
accumulate higher concentrations of cytotoxic
metabolites (Turon et al., 1998). Another example is
the production of halichondrin B by Lissodendoryx
sp., which varies seasonally, with depth, and with
the condition of the sponge. Halichondrin B yields
could be enhanced by an order of magnitude during
serial cloning, suggesting a defensive response to
damage (Battershill et al., 2002). The ability to
stimulate the production of secondary metabolites
by sponges is an important consideration when one
wants to harvest compounds from sponges for the
production of potential new medicines.
Conclusion
Marine sponges produce an enormous array of anti-
tumor, antiviral, antiinflammatory, immunosup-
pressive, antibiotic, and other bioactive molecules
that can affect the pathogenesis of many human dis-
eases. The relationship between the chemical struc-
tures of the secondary metabolites from sponges and
the diseases they affect is usually not obvious. Dif-
ferent components affect the targeted disease by dif-
ferent mechanisms (e.g., microtubule stabilization or
interaction with DNA to combat tumors). Moreover,
inhibitors of transcription may be effective against
both cancer and viral diseases. To make things more
complex, there are many relations between, for in-
stance, inflammation, cancer, and viral infections via
the immune system, which plays a key role in certain
responses of the body to these diseases. Chronic
inflammation of the lungs by cigarette smoke often
leads to lung cancer (Ohwada et al., 1995) and cervical
and liver cancer can follow chronic inflammation
caused by papilloma viruses (Smith-McCune et al.,
1996) and hepatitis B and C viruses, respectively (Zhu
et al., 1997). In addition, limited activity testing (e.g.,
only on cell growth inhibition and not on antiviral
properties) yields an incomplete overview of the ac-
tual properties of the metabolites. Finally, for many
bioactive molecules from sponges, the exact mode of
action and their origin (sponge or symbiont) are still
unclear. Most bioactive metabolites from sponges are
inhibitors of certain enzymes, which often mediate or
produce mediators of intracellular or intercellular
messengers involved in the pathogenesis of a disease.
As this is usually a cascade of reactions inside the cell
or tissue, many enzymes in the cascade are targets for
potential therapy. The different enzymes in the cas-
cade can be structurally completely different proteins;
therefore, it is not surprising that a wide range of
metabolites can be used for the treatment of one dis-
ease. This applies in particular to a complex disease,
Table 9. Examples of Antifouling Products from Sponges
Compound Compound class Species/order Reference
Kalihinene X Isocyanoterpenoid Acanthella cavernosa/
Halichondrida
Okino et al., 1995
Kalihipyran B Isocyanoterpenoid Acanthella cavernosa/
Halichondrida
Okino et al., 1996
10b-Formarnidokalihinol Isocyanoterpenoid Acanthella cavernosa/
Halichondrida
Hirota et al., 1996
Pseudoceratidine 2 Dibromopyrrole-containing
spermidine derivative
Pseudoceratina purpurea/
Verongida
Tsukamoto et al., 1996b
Ceratinamide A and B Bromotyrosine derivative Pseudoceratina purpurea/
Verongida
Tsukamoto et al., 1996a
C22 ceramide Ceramide Haliclona koremella/
Haplosclerida
Hattori et al., 1998
Formoside Striterpene glycoside,
sterol diperoxide
Erylus formosus/
Astrophorida
Kubanek et al., 2002
Lendenfeldia chondrodes /
Dictyoceratida
Sera et al., 1999
Axinyssimides Sesquiterpene carbonimide
cdichlorides
Axinyssa sp./Halichondrida Hirota et al., 1998
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such as cancer, which is affected by so many different
factors. Furthermore, antiviral molecules also appear
to encamps a wide array of chemical structures, such
as peptides, lipids, alkaloids, sterols, oligonucleo-
tides, and a phenolic macrolide. A similar diverse
pattern is observed for antibacterial and immuno-
suppressive metabolites. Most compounds that dis-
play antiinflammatory activity are sesterterpenoids.
Nevertheless, in these cases the activity of the sponge
metabolites is concentrated on certain steps; for in-
stance, most antiinflammatory compounds act
against phospholipase A2.
The potency of sponge-derived medicines lies in
the fact that each of these thousands of metabolites
and their derivatives has its own specific dose-re-
lated inhibitory effect, efficacy, and potential
(diminished) side effects that determine its suitabil-
ity for medicinal use. In addition, the skeleton or
active core of these molecules may be used as a
vehicle to develop derivatives with their own spe-
cific efficacy and side effects. Therefore, the most
important challenge in transforming bioactive mol-
ecules into medicines is now to screen the treasure-
house of sponge metabolites and select those that
display a specific mode of action with the desired
characteristics against a disease. An important
question for the future remains how to actually
prepare the potential novel drugs on a large scale.
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